(-0.08%) 5 464.84 points
(0.10%) 39 150 points
(0.12%) 17 739 points
(-0.01%) $80.82
(-5.04%) $2.62
(-0.86%) $2 310.80
(-0.24%) $28.80
(3.19%) $1 017.90
(0.35%) $0.936
(0.75%) $10.68
(0.53%) $0.792
(-0.30%) $87.23
2.19% € 8.10
Live Chart Being Loaded With Signals
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally...
Stats | |
---|---|
Volumen de hoy | 710 |
Volumen promedio | 4 616 |
Capitalización de mercado | 545.76M |
EPS | €-0.0406 ( Q4 | 2024-04-04 ) |
Próxima fecha de ganancias | ( €0 ) 2024-08-01 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E |
-50.65 (Sector) 42.63 (Industry) 24.32 |
ATR14 | €0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2004-05-27 | Camden Partners Strategic Fund Ii A Lp | Buy | 5 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 1 transactions |
Buy: 5 000 | Sell: 0 |
Pharming Group N.V. Correlación
10 Correlaciones Más Positivas | |
---|---|
SAGE | 0.908 |
PEV | 0.891 |
AUVI | 0.89 |
HCAT | 0.889 |
OPOF | 0.887 |
SHY | 0.879 |
PDCO | 0.878 |
SFST | 0.878 |
BSBK | 0.875 |
IBTG | 0.874 |
10 Correlaciones Más Negativas | |
---|---|
PWP | -0.878 |
KALU | -0.864 |
VCTR | -0.857 |
FANG | -0.855 |
NKTR | -0.854 |
QNST | -0.853 |
PRIM | -0.849 |
FRLA | -0.849 |
AEYE | -0.848 |
SLAM | -0.846 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pharming Group N.V. Finanzas
Annual | 2023 |
Ingresos: | €245.32M |
Beneficio Bruto: | €220.10M (89.72 %) |
EPS: | €-0.160 |
FY | 2023 |
Ingresos: | €245.32M |
Beneficio Bruto: | €220.10M (89.72 %) |
EPS: | €-0.160 |
FY | 2022 |
Ingresos: | €205.62M |
Beneficio Bruto: | €188.06M (91.46 %) |
EPS: | €0.210 |
FY | 2021 |
Ingresos: | €167.68M |
Beneficio Bruto: | €149.86M (89.37 %) |
EPS: | €0.210 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico